First customer sites include the University of Arkansas for Medical Sciences, MUSC Health, and Calif.-based Acacia Clinics and Kaizen Brain Center BURLINGAME, Calif.--(BUSINESS WIRE)--Magnus Medical, ...
Nine sites in U.S. to participate in Open Label Optimization (OLO) study First time a large number of adults have access to SAINT™ therapy Actively enrolling up to 1,000 adults BURLINGAME, ...
For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S. FDA enabling at-home use of neuromodulation devices may provide a bright ...
Magnus Medical, a developer of brain stimulation technology to treat neuropsychiatric disorders, has treated its first participants in its Open Label Optimization (OLO) clinical trial evaluating the ...
BrainsWay’s strategic investment in Neurolief paved the way for the first and only FDA approved at-home neuromodulation device with Class III Premarket Approval labeling for MDD patients who failed ...
This investment marks BrainsWay’s entrance into the market for mental health therapies that can be administered outside of a clinic, including at home Neurolief’s breakthrough Proliv™Rx device is ...
Selective serotonin reuptake inhibitors (SSRIs) are considered the first-line, gold standard treatment for depression. However, their use is not without limitations, with commonly reported side ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results